ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol “OBSV” on January 26, 2017. Today ObsEva CEO Ernest Loumaye will ring the Nasdaq stock market opening bell in celebration of the IPO.
ObsEva announced today the pricing of its initial public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The Swiss biotech company will raise between $90 million and $110 million.
Founded in Switzerland in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. ObsEva is advancing a pipeline of orally-administered, clinical-stage innovative compounds to treat women’s reproductive health conditions from conception to birth. The company is advancing three product candidates in clinical development for four indications.
We published an extensive interview with Ernest Loumaye, Founder and CEO of ObsEva last year.
Picture: Fotolia.com - Gary
(SK)
Please login or sign up to comment.
Commenting guidelines